Age-Related Macular Degeneration as a Disease of Retinal Metabolic Failure
Age-related macular degeneration is usually described as a problem of aging and drusen. But a growing body of research points to something deeper: a slow failure of energy metabolism in the retina and the cells that support it. In this episode, Dr. Saikumar Gandapodi, Founder and Director of Netra Eye Institute, reframes AMD as a disease of metabolic exhaustion in the retinal pigment epithelium and photoreceptors.
We explore why the macula is metabolically the most demanding tissue in the body, how mitochondrial dysfunction, oxidative stress, and lipid handling failures set the stage for drusen and cell death, and what conventional care does well. Dr. Gandapodi explains the evidence behind anti-VEGF therapy and the AREDS trials, and where meaningful gaps remain.
He also introduces Netra Restoration Therapy, an integrative, adjunct approach aimed at supporting mitochondrial function, oxidative balance, and ocular blood flow. Throughout, the conversation stays honest about what is established, what is emerging, and what remains hypothesis.
Transcript
[on-hold music] Welcome to the Netra Eye Institute Podcast,
Speaker:where modern vision science meets the wisdom of integrative ophthalmology.
Speaker:Today, we are joined by Dr. Saikumar Gandapodi,
Speaker:founder and director of Netra Eye Institute,
Speaker:whose work is dedicated to redefining how patients understand and approach chronic
Speaker:and degenerative eye conditions.
Speaker:His goal is simple:
Speaker:to help patients, families, and clinicians explore a more comprehensive and
Speaker:integrative approach to long-term eye health.
Speaker:This is the Netra Eye Institute Podcast. Let's begin.
Speaker:Welcome back to the show. Today, we're looking at macular degeneration from an
Speaker:angle most people never hear about,
Speaker:not as a disease of old blood vessels or spots on a scan, but as a disease of
Speaker:energy.
Speaker:My guest is Dr. Saikumar Gandapodi, board certified in Oriental medicine, a
Speaker:practitioner of Ayurvedic medicine, and founder and director of the Netra Eye
Speaker:-Institute. Dr. Gandapodi, welcome. -Thank you. It's a pleasure to be here.
Speaker:This is a topic I care about deeply because I think the metabolic view changes
Speaker:how we think about the disease very early on.
Speaker:Let's start there. When you say AMD is a disease of retinal metabolic failure, what
Speaker:-do you actually mean? -I mean the core problem is energy. The
Speaker:macula is one of the most metabolically hungry tissues in the entire body.
Speaker:Photoreceptors and the cells that support them burn an enormous amount of fuel to
Speaker:keep vision running.
Speaker:When that energy machinery starts to fail, the visible things we diagnose, drusen,
Speaker:atrophy, leaky vessels, come later. They're downstream.
Speaker:Why is the macula so metabolically demanding in the first place?
Speaker:Two reasons.
Speaker:Photoreceptors constantly regenerate their light-sensing outer segments.
Speaker:They shed tips every day and rebuild them,
Speaker:and they run phototransduction, which is a heavy energy process,
Speaker:so they're packed with mitochondria and demand a steady supply of oxygen and
Speaker:nutrients.
Speaker:That high demand is exactly what makes them vulnerable when supply or cellular
Speaker:-repair falters. -You keep mentioning the support cells.
Speaker:Tell me about the retinal pigment epithelium, the RPE, because I think
Speaker:-that's central to your argument. -The RPE is the unsung hero. It's a single
Speaker:layer of cells sitting behind the photoreceptors.
Speaker:Every day, it digests the shed photoreceptor tips, recycles vitamin A,
Speaker:transports nutrients in and waste out, and manages oxidative stress.
Speaker:It's doing janitorial and metabolic work nonstop.
Speaker:In AMD, the evidence strongly points to the RPE as an early failure point.
Speaker:So what happens as that RPE machinery ages and starts to struggle?
Speaker:It falls behind on its cleanup.
Speaker:Undigested material accumulates as lipofuscin inside the cells and as drusen,
Speaker:those fatty deposits, beneath them.
Speaker:Mitochondria in the RPE become damaged and less efficient. This is fairly well
Speaker:established from human tissue studies. RPE mitochondria show structural and
Speaker:functional decline with age and more so in AMD eyes.
Speaker:Let's slow down on mitochondria.
Speaker:How does mitochondrial dysfunction actually drive the disease forward?
Speaker:Think of it as a vicious cycle. Damaged mitochondria make less energy and leak
Speaker:more reactive oxygen species.
Speaker:That oxidative stress damages mitochondrial DNA, lipids, and proteins,
Speaker:which makes the mitochondria work even worse. The RPE is bathed in light and
Speaker:oxygen, so it already lives in a pro-oxidant environment.
Speaker:Over decades, that cycle wears the cells down.
Speaker:And where does oxidative stress fit alongside that? Is it cause or
Speaker:consequence?
Speaker:Honestly, both. They feed each other. Oxidative stress is one of the best
Speaker:supported mechanisms in AMD.
Speaker:The whole rationale behind antioxidant supplementation grew out of that
Speaker:understanding.
Speaker:But oxidative damage and metabolic failure aren't separate stories. They're the same
Speaker:story told from two angles.
Speaker:You mentioned lipids and drusen.
Speaker:There's a lot of interest now in AMD as partly a lipid handling problem.
Speaker:-What's the evidence there? -Drusen are rich in lipids and cholesterol,
Speaker:and genetic studies have repeatedly linked AMD risk to genes involved in lipid
Speaker:metabolism and the complement immune system. So there's real support that the
Speaker:RPE's ability to process and export fats breaks down. When lipids build up between
Speaker:the RPE and its blood supply, they may physically impair nutrient exchange, which
Speaker:starves the cells further. That's a metabolic bottleneck.
Speaker:You just brought up the complement system and inflammation. How does that connect to
Speaker:-the metabolic picture? -The complement link is one of the
Speaker:strongest findings in AMD genetics. Variants in complement factor H, for
Speaker:example, clearly raise risk.
Speaker:Chronic low-grade inflammation and metabolic stress reinforce each other.
Speaker:Stressed, energy-starved cells send out distress signals. The immune system
Speaker:responds. That inflammatory environment further burdens already tired cells. It's
Speaker:-a slow, smoldering process, not a fire. -Let's talk about blood flow. Does reduced
Speaker:circulation to the retina play a role,
Speaker:or is that overstated?
Speaker:It plays a role. The RPE and photoreceptors get most of their oxygen
Speaker:and nutrients from the choroid, the vascular bed behind them.
Speaker:Imaging studies show the choroid thins and its blood flow drops in AMD.
Speaker:If you have a tissue with enormous energy demand and you reduce its fuel delivery,
Speaker:you compound the metabolic failure.
Speaker:So circulation is part of the supply side of the equation.
Speaker:Let me put the conventional picture in place.
Speaker:What does standard ophthalmology do well for AMD today?
Speaker:A lot. And I want to be clear, I have deep respect for it.
Speaker:For wet AMD, the type with abnormal leaky vessels, anti-VEGF injections have been
Speaker:genuinely transformative in preserving vision.
Speaker:That's supported by large, high-quality clinical trials.
Speaker:For dry AMD, the AREDS and AREDS2 trials showed a specific antioxidant and zinc
Speaker:formula modestly slows progression in people at higher risk.
Speaker:Those are real established tools.
Speaker:So where are the limits?
Speaker:Where does conventional care leave gaps?
Speaker:Two big gaps. First, anti-VEGF treats the consequence, the abnormal vessels, not the
Speaker:underlying metabolic decline that led there.
Speaker:Second, for dry AMD and geographic atrophy, options have been very limited.
Speaker:There are newer complement-targeting drugs approved for geographic atrophy that slow
Speaker:lesion growth somewhat, but they don't restore vision, and the benefit is modest.
Speaker:So there's genuine room for approaches that address the metabolic root earlier.
Speaker:That's a good bridge to your work. Tell me what Netra Restoration Therapy actually
Speaker:is.
Speaker:Netra Restoration Therapy, or NRT, is an integrative full-spectrum approach
Speaker:designed to support the retina through several biological pathways at once:
Speaker:mitochondrial function, oxidative balance, ocular blood flow, inflammatory
Speaker:regulation, and overall cellular resilience.
Speaker:The logic is simple. If AMD is a multifactorial metabolic problem, a
Speaker:single-target intervention may not be enough.
Speaker:I want to be very clear, though. It's an adjunct. It complements standard
Speaker:ophthalmic care. It doesn't replace it.
Speaker:Why a multi-target approach rather than one clean drug against one pathway?
Speaker:Because the disease isn't one pathway. You've got mitochondrial decline,
Speaker:oxidative stress, lipid handling, inflammation, and circulation all
Speaker:interacting. This is where the concept of network pharmacology becomes useful, the
Speaker:idea that a complex multi-component intervention can nudge several pathways
Speaker:gently rather than hitting one hard.
Speaker:Herbal formulas, for instance, contain many phytochemicals acting on multiple
Speaker:targets. That's increasingly how they're being studied.
Speaker:You come from both Ayurvedic and Chinese medicine traditions. How do you translate
Speaker:those older frameworks without overselling them?
Speaker:Carefully and always as parallels, not as scientific equivalents. In Chinese
Speaker:medicine, a concept like blood stasis can be a useful interpretive lens for what
Speaker:we'd biomedically call impaired microcirculation. In Ayurveda,
Speaker:disturbances of rakta dhatu or a decline in ojas loosely map onto ideas about
Speaker:tissue nourishment and vitality.
Speaker:But I'm explicit with patients. These are conceptual frameworks that guide thinking,
Speaker:not proven mechanisms. The biology is what we test.
Speaker:Let's get concrete on the mitochondrial support side.
Speaker:-What's actually studied there? -There's laboratory and some early clinical
Speaker:interest in compounds that support mitochondrial function and reduce
Speaker:oxidative stress, things in the broad category of antioxidants and metabolic
Speaker:cofactors.
Speaker:The AREDS2 formula itself with lutein and zeaxanthin is the strongest example with
Speaker:real human trial support.
Speaker:Beyond that, much of the mitochondrial support work is still in cell and animal
Speaker:models. I'd call it mechanistically plausible and emerging, not established
Speaker:for reversing AMD.
Speaker:That's an honest line to draw.
Speaker:What about lutein and zeaxanthin specifically?
Speaker:-Why do those have better footing? -They're carotenoids that concentrate in
Speaker:the macula. They literally form the macular pigment.
Speaker:They filter damaging blue light and act as antioxidants right where the metabolic
Speaker:stress is highest.
Speaker:AREDS2 gave us human trial evidence supporting their inclusion.
Speaker:That's a nice example where a nutritional metabolically oriented intervention
Speaker:crossed from theory into evidence.
Speaker:You mentioned blood flow.
Speaker:Are there integrative approaches to circulation that have any support?
Speaker:There's interest in certain botanicals traditionally used to improve
Speaker:microcirculation
Speaker:and some acupuncture research exploring ocular blood flow.
Speaker:I'll be candid. The human evidence for those in AMD specifically is early and
Speaker:mixed.
Speaker:I include circulation support in NRT because the mechanism is reasonable and
Speaker:choroidal flow is genuinely reduced in AMD.
Speaker:But I don't present it as proven to change outcomes.
Speaker:There's growing talk of a gut-eye axis.
Speaker:Does that have any bearing on a metabolic disease like AMD?
Speaker:It's an intriguing and very active area.
Speaker:The reasoning is that the gut microbiome influences systemic inflammation and lipid
Speaker:metabolism,
Speaker:both of which are relevant to AMD.
Speaker:Some observational and animal work supports a connection.
Speaker:But I want to be honest, this is largely hypothesis-generating right now.
Speaker:We don't have strong human trials showing that changing the microbiome changes AMD
Speaker:progression.
Speaker:It's a direction, not a destination.
Speaker:Diet and lifestyle come up constantly with AMD.
Speaker:What’s actually well-supported there versus wishful thinking?
Speaker:The strongest, most established lifestyle fact is smoking. It’s a major modifiable
Speaker:risk factor, and quitting matters enormously.
Speaker:Beyond that, observational studies link dietary patterns rich in leafy greens,
Speaker:fish, and low in processed foods, Mediterranean-style eating, with lower AMD
Speaker:risk and slower progression.
Speaker:That’s consistent with the metabolic view. You’re supporting the tissue’s fuel and
Speaker:reducing oxidative and inflammatory load.
Speaker:If AMD really starts as metabolic failure years before symptoms,
Speaker:does that change how early we should be acting?
Speaker:I think that’s the most important takeaway.
Speaker:If the metabolic decline begins long before drusen are visible, then prevention
Speaker:and early support may matter far more than we’ve appreciated.
Speaker:Protecting mitochondrial health, managing cardiovascular and metabolic risk, not
Speaker:smoking, eating well—these are low-risk steps we can start decades before disease
Speaker:shows up on a scan.
Speaker:How do you talk to a patient who comes in with early dry AMD and wants to know what
Speaker:to do?
Speaker:First, I make sure they’re anchored in proper ophthalmic monitoring: regular
Speaker:imaging, watching for conversion to wet AMD, because that needs prompt treatment.
Speaker:Then we discuss AREDS2 if appropriate for their risk level.
Speaker:Then we build the integrative layer around that: diet, smoking cessation, metabolic
Speaker:health, and NRT as an adjunct.
Speaker:I never frame it as a cure, and I never ask anyone to skip their retina
Speaker:-specialist. -Is there any risk in the integrative
Speaker:approach patients should know about?
Speaker:Yes. Supplements and botanicals aren’t automatically safe.
Speaker:High-dose zinc, certain herbs, and interactions with medications like blood
Speaker:thinners are real concerns.
Speaker:Quality and dosing vary widely, so this should always be done with a knowledgeable
Speaker:clinician who coordinates with your eye doctor, not as self-experimentation from
Speaker:-the internet. -Looking ahead, what excites you most about
Speaker:where the science is going?
Speaker:I’m excited that the field is moving upstream toward mitochondrial biology,
Speaker:lipid handling, and complement regulation, rather than only treating late-stage
Speaker:vessels.
Speaker:If we can develop reliable early biomarkers of metabolic stress in the RPE,
Speaker:we could intervene years earlier. And I’m hopeful that rigorous trials will
Speaker:eventually sort out which integrative pieces truly help. That’s the honest path
Speaker:forward.
Speaker:If a listener remembers just one idea from today,
Speaker:what should it be?
Speaker:That macular degeneration may begin as a quiet energy crisis in the retina,
Speaker:long before you notice anything.
Speaker:That reframing gives us more to work with, earlier, and across the whole body.
Speaker:Partner with your ophthalmologist, protect your metabolic health, and treat
Speaker:integrative care as a thoughtful complement, never a substitute.
Speaker:Dr. Gandapodi, this has been genuinely illuminating.
Speaker:Thank you for the rigor and the honesty.
Speaker:Thank you. It’s been a real pleasure to explore this with you.
